Vanguard Fiduciary Trust
AXSM icon

Vanguard Fiduciary Trust’s Axsome Therapeutics AXSM Stock Holding History

Vanguard Fiduciary Trust’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.5M Sell
279,738
-15,401
-5% -$3.34M 0.02% 700
2026
Q1 		$49.9M Buy
+295,139
New +$51M 0.01% 787

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Fiduciary Trust's AXSM Position: Q2 2026 in Review

Vanguard Fiduciary Trust reduced its Axsome Therapeutics (AXSM) stake by 5.2% in Q2 2026, selling an estimated $3.34M and leaving 279,738 shares worth $68.5M. The position accounts for 0.02% of the portfolio, ranked #700.

Vanguard Fiduciary Trust first reported a position in AXSM in Q1 2026 and has held it in 2 quarters since. 500 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Vanguard Fiduciary Trust held 279,738 shares of Axsome Therapeutics worth $68.5M as of Q2 2026.
  • Vanguard Fiduciary Trust sold 15,401 Axsome Therapeutics shares in Q2 2026, an estimated $3.34M.
  • Axsome Therapeutics made up 0.02% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #700 holding.
  • Vanguard Fiduciary Trust first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 500 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.